Literature DB >> 22850484

LRRK2 expression is enriched in the striosomal compartment of mouse striatum.

Wim Mandemakers1, An Snellinx, Michael J O'Neill, Bart de Strooper.   

Abstract

In spite of a clear genetic link between Parkinson's disease (PD) and mutations in LRRK2, cellular localization and physiological function of LRRK2 remain debated. Here we demonstrate the immunohistochemical localization of LRRK2 in adult mouse and early postnatal mouse brain development. Antibody specificity is verified by absence of specific staining in LRRK2 knockout mouse brain. Although LRRK2 is expressed in various mouse brain regions (i.e. cortex, thalamus, hippocampus, cerebellum), strongest expression is detected in striatum, whereas LRRK2 protein expression in substantia nigra pars compacta in contrast is low. LRRK2 is highly expressed in striatal medium spiny neurons (MSN) and few cholinergic interneurons. LRRK2 expression is undetectable in other interneurons, oligodendrocytes or astrocytes of the striatum. Interestingly, LRRK2 expression is associated with striosome specific markers (i.e. MOR1, RASGRP1). Analysis of LRRK2 expression during early postnatal development and in LRRK2 knockout mice, demonstrates that LRRK2 is not required for generation or maintenance of the striosome compartment. Comparing LRRK2-WT, LRRK2-R1441G transgenic and non-transgenic mice, changes of LRRK2 expression in striosome/matrix compartments can be detected. The findings rule out a specific requirement of LRRK2 in striosome genesis but suggest a functional role for LRRK2 in striosomes.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22850484     DOI: 10.1016/j.nbd.2012.07.017

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  31 in total

Review 1.  Functional and behavioral consequences of Parkinson's disease-associated LRRK2-G2019S mutation.

Authors:  Deanna L Benson; Bridget A Matikainen-Ankney; Ayan Hussein; George W Huntley
Journal:  Biochem Soc Trans       Date:  2018-12-04       Impact factor: 5.407

2.  Progressive dopaminergic alterations and mitochondrial abnormalities in LRRK2 G2019S knock-in mice.

Authors:  M Yue; K M Hinkle; P Davies; E Trushina; F C Fiesel; T A Christenson; A S Schroeder; L Zhang; E Bowles; B Behrouz; S J Lincoln; J E Beevers; A J Milnerwood; A Kurti; P J McLean; J D Fryer; W Springer; D W Dickson; M J Farrer; H L Melrose
Journal:  Neurobiol Dis       Date:  2015-03-31       Impact factor: 5.996

3.  LRRK2 secretion in exosomes is regulated by 14-3-3.

Authors:  Kyle B Fraser; Mark S Moehle; João P L Daher; Philip J Webber; Jeri Y Williams; Carrie A Stewart; Talene A Yacoubian; Rita M Cowell; Terje Dokland; Tong Ye; Dongquan Chen; Gene P Siegal; Robert A Galemmo; Elpida Tsika; Darren J Moore; David G Standaert; Kyoko Kojima; James A Mobley; Andrew B West
Journal:  Hum Mol Genet       Date:  2013-07-25       Impact factor: 6.150

4.  Genome-Wide Association Analysis of the Sense of Smell in U.S. Older Adults: Identification of Novel Risk Loci in African-Americans and European-Americans.

Authors:  Jing Dong; Annah Wyss; Jingyun Yang; T Ryan Price; Aude Nicolas; Michael Nalls; Greg Tranah; Nora Franceschini; Zongli Xu; Claudia Schulte; Alvaro Alonso; Steven R Cummings; Myriam Fornage; Dmitri Zaykin; Leping Li; Xuemei Huang; Stephen Kritchevsky; Yongmei Liu; Thomas Gasser; Robert S Wilson; Philip L De Jager; Andrew B Singleton; Jayant M Pinto; Tamara Harris; Thomas H Mosley; David A Bennett; Stephanie London; Lei Yu; Honglei Chen
Journal:  Mol Neurobiol       Date:  2016-11-23       Impact factor: 5.590

5.  Differential LRRK2 expression in the cortex, striatum, and substantia nigra in transgenic and nontransgenic rodents.

Authors:  Andrew B West; Rita M Cowell; João P L Daher; Mark S Moehle; Kelly M Hinkle; Heather L Melrose; David G Standaert; Laura A Volpicelli-Daley
Journal:  J Comp Neurol       Date:  2014-04-12       Impact factor: 3.215

Review 6.  The complex relationships between microglia, alpha-synuclein, and LRRK2 in Parkinson's disease.

Authors:  J Schapansky; J D Nardozzi; M J LaVoie
Journal:  Neuroscience       Date:  2014-10-02       Impact factor: 3.590

Review 7.  Interrogating Parkinson's disease associated redox targets: Potential application of CRISPR editing.

Authors:  M A Artyukhova; Y Y Tyurina; C T Chu; T M Zharikova; H Bayır; V E Kagan; P S Timashev
Journal:  Free Radic Biol Med       Date:  2019-06-12       Impact factor: 7.376

8.  Selective expression of Parkinson's disease-related Leucine-rich repeat kinase 2 G2019S missense mutation in midbrain dopaminergic neurons impairs dopamine release and dopaminergic gene expression.

Authors:  Guoxiang Liu; Carmelo Sgobio; Xinglong Gu; Lixin Sun; Xian Lin; Jia Yu; Loukia Parisiadou; Chengsong Xie; Namratha Sastry; Jinhui Ding; Kelly M Lohr; Gary W Miller; Yolanda Mateo; David M Lovinger; Huaibin Cai
Journal:  Hum Mol Genet       Date:  2015-06-29       Impact factor: 6.150

9.  LRRK2 regulates synaptogenesis and dopamine receptor activation through modulation of PKA activity.

Authors:  Loukia Parisiadou; Jia Yu; Carmelo Sgobio; Chengsong Xie; Guoxiang Liu; Lixin Sun; Xing-Long Gu; Xian Lin; Nicole A Crowley; David M Lovinger; Huaibin Cai
Journal:  Nat Neurosci       Date:  2014-01-26       Impact factor: 24.884

10.  Leucine-rich repeat kinase 2 regulates Sec16A at ER exit sites to allow ER-Golgi export.

Authors:  Hyun Jin Cho; Jia Yu; Chengsong Xie; Parvathi Rudrabhatla; Xi Chen; Junbing Wu; Loukia Parisiadou; Guoxiang Liu; Lixin Sun; Bo Ma; Jinhui Ding; Zhihua Liu; Huaibin Cai
Journal:  EMBO J       Date:  2014-09-08       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.